Search Results for “EC” – Page 550 – media

Rumours Allergan is looking to offload $5bn women’s health unit

According to a piece by Bloomberg, Allergan is looking at options to divest its women’s health unit in a move that could potentially reap about $5 billion.
- Source: pharmafile
- 607
- April 6, 2018
Allergan biosimilar Company Insight
FDA refuses to review Alkermes’ depression drug, demands additional clinical trials

The FDA has told Alkermes it needs to see data from “additional well-controlled clinical trials” before it will review a filing for approval of depression drug ALKS 5461. Alkermes plans to appeal the ruling, but at this stage it looks like the biotech’s attempt to get a mixed set of data past the FDA has failed.
- Source: fiercebiotech
- 695
- April 6, 2018
ALKS 5461 Depression New Approvals
Overriding EHR Alerts May Up Adverse Drug Events

Such alerts remind clinicians about everything from a patient's drug allergies, to possible drug interactions, to dosing guidelines, to lab testing guidance. Clinicians can either follow the alerts' recommendations, override them, or ignore them.
- Source: MedPageToday
- 668
- April 6, 2018
digital health EHR Researches
Singapore’s Aslan stalks $86M IPO to fund cancer pipeline

Aslan wants to list on the U.S. exchange under the ASLN symbol.
- Source: fiercebiotech
- 541
- April 5, 2018
Aslan Market Views varlitinib
Apple’s PHR health system partnerships up threefold

Health Records is based on the interoperability standard FHIR and collects encrypted medical data on allergies, immunizations, lab results, medications, procedures, vital signs and conditions. Users will receive notifications when their data are updated.
- Source: HealthCareDive
- 935
- April 5, 2018
Company Insights mHealth PHR
Using CRISPR to introduce beneficial but rare gene mutations in sickle cell

People who suffer from the inherited disease sickle cell disease have defects in their hemoglobin, the blood molecule that transports vital oxygen throughout the body. But a small percentage of patients with the disease have beneficial gene mutations that lessen their symptoms. The mutations switch on a gene that produces fetal hemoglobin—a type of the blood molecule that the body normally stops producing in infancy. The lifelong production of fetal hemoglobin helps shield those sickle cell patients from the worst effects of the disease.
- Source: fiercebiotech
- 470
- April 5, 2018
Researches sickle cell disease
EU reviews for Sanofi’s Dupixent, cemiplimab

European regulators have agreed to review Sanofi and Regeneron’s Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma.
- Source: pharmatimes
- 936
- April 4, 2018
asthma FDA New Approvals Sanofi
Partner Therapeutics (PTx) Acquires Leukine® from Sanofi

Purchase includes Lynnwood, WA Biologics Manufacturing Facility
- Source: finance.yahoo
- 634
- April 4, 2018
acute myelogenous leukemia FDA Leukine Sanofi
Eisai Submits Supplemental New Drug Application (sNDA) to FDA for FYCOMPA® (perampanel) Pediatric Indications

Eisai Inc. announced that it has submitted a supplemental New Drug Application (sNDA) for priority review to the U.S. Food and Drug Administration (FDA) for its antiepileptic drug FYCOMPA® (perampanel) CIII as monotherapy and adjunctive use for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures in pediatric patients (ages 2 to less than 12 years). The submission also proposes a pediatric indication for monotherapy and adjunctive use for primary generalized tonic-clonic seizures (PGTC) in children (ages 2 to less than 12 years) with epilepsy. The sNDA is for both the FYCOMPA tablet and oral suspension formulations.
- Source: prnewswire
- 642
- April 4, 2018
Eisai FDA FYCOMPA® New Approvals
On-demand health concierge Accolade lands another $50M in funding

Last week on-demand healthcare concierge for provider employers Accolade received $50 million in funding led by Andreessen Horowitz, Carrick Capital Partners, Madrona Venture Group, and McKesson Ventures, with participation from Cross Creek Advisors and Madera Technologies.
- Source: MobiHealthNews
- 740
- April 4, 2018
Company Insights funding healthcare

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.